Prophylactic Use of Milrinone After Congenital Heart Surgery in Infants
Status:
Unknown status
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This randomized, multi-center, double-blinded, placebo-controlled study is designed to
evaluate the efficacy and safety of milrinone compared with placebo in participants after
corrective surgery for congenital heart disease. Participants will be randomized in a 1:1
ratio within 90 minutes after arriving in the intensive care unit (ICU), to receive either
intravenous milrinone or placebo for 36 hours. Participants will be stratified according
Vasoactive Inotrope Score after arriving in the ICU.